A Study To Investigate The Safety And Efficacy Properties Of PF-00547659 In Patients With Active Ulcerative Colitis

A Randomized, Double-Blind (Sponsor Open), Placebo Controlled, Dose Escalating, Parallel Group, Multi-Centre Study To Investigate The Safety, Toleration, Pharmacokinetics And Pharmacodynamics Of Single And Multiple Intravenous/Sub-Cutaneous Doses Of PF-00547659 In Patients With Active Ulcerative Colitis.

study to investigate the safety and efficacy properties of PF-00547659 in patients with active ulcerative colitis

Inclusion Criteria:

• A positive histological diagnosis of UC ≥3 months prior to entry into the study. If a histological diagnosis is not available but all signs and symptoms suggest UC, the subject's eligibility should be discussed with Pfizer.
• Active UC as defined by a score of ≥6 on the Mayo score.
• An endoscopic (by flexible sigmoidoscopy) sub-score of ≥2 on the Mayo score determined within 7 days of first dosing.

Exclusion Criteria:

• Subjects with UC, which is confined to a proctitis on a flexible sigmoidoscopy.
• Subjects who have had surgery as a treatment for UC or are likely to require surgery within the duration of the study.
• Subjects displaying clinical signs of ischemic colitis.